SCHEMBL28822133

SCHEMBL28822133

COC(=O)C1=CC=NNC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 2/20 0.43
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 4/20 0.36
TSHR P16473 2/20 0.35
LMNA P02545 2/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
THRB P10828 1/20 0.35
CHRM1 P11229 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
CA12 O43570 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
BLM P54132 1/20 0.34
MCOLN3 Q8TDD5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27519680 0.68 PTPN1 (0.39) CHRM3KDM4EALDH1A1TSHRLMNA
SCHEMBL27751908 0.68 CHRM3 (0.44) CHRM3KDM4EALDH1A1TSHRLMNA
SCHEMBL24806520 0.67 CHRM3 (0.43) CHRM3KDM4EALDH1A1TSHRLMNA
SCHEMBL5906945 0.66 PTPN1 (0.50) CHRM3KDM4EALDH1A1TSHRLMNA
SCHEMBL19852053 0.66 CHRM3 (0.35) CHRM3KDM4EALDH1A1TSHRLMNA
SCHEMBL5798986 0.64
SCHEMBL21547920 0.63 CHRM3 (0.40) CHRM3ALDH1A1TSHRLMNACHRM2
SCHEMBL15515022 0.63 CHRM3 (0.43) CHRM3KDM4EALDH1A1TSHRLMNA
SCHEMBL29107802 0.62 NPSR1 (0.33) KDM4EALDH1A1TSHRNPSR1MAPK1
SCHEMBL10431184 0.62 CHRM3 (0.50) CHRM3KDM4EALDH1A1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110678459-B 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer 拜耳股份公司 2023-04-04 CN claimed
CN-114786674-A Combination of an AHR inhibitor and a PD1 inhibitor antibody and use thereof in the treatment of cancer 拜耳公司 2022-07-22 CN claimed
CN-114786674-A Combination of an AHR inhibitor and a PD1 inhibitor antibody and use thereof in the treatment of cancer 拜耳公司 2022-07-22 CN disclosed
WO-2022111708-A1 DEUTERATED 2-ARYLHETEROCYCLE-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 苏州泽璟生物制药股份有限公司 2022-06-02 WO disclosed